Abstract: The invention relates to the use of galanthamine, as free base or as acid addition salt, for the treatment of cerebral, central nervous or psychiatric symptoms, defunctionalization manifestations or disorders occurring through intake of psychotropic substances as a consequence of occasional or chronic abuse of addictive substances, intoxicants or medicines, or as side effects of the use, especially repeated or prolonged, as intended of medicaments, or as an effect of use, in particular repeated or prolonged, not as intended of medicaments, or as a result of acute poisoning by psychotropic toxic substances, or as a result of chronic exposure to toxic substances with a psychotropic effect in humans or other vertebrates.

Abstract: Administration forms for application to the skin or mucosa, comprising a carrier matrix and at least one active substance, are characterized in that the carrier matrix has a plurality of particles having open pores or containing capillary spaces, said particles serving as active substance reservoir and containing at least one active substance.

Abstract: (S)-N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate (formula (1)) or at least one active ingredient according to formula (2) for the preventive protection of people from poisoning caused by cholinesterase inhibitors.

Abstract: A method for the protection of a human being against any health impairment as a result of the ingestion of the whole or parts of a transdermal therapeutic system containing at least one pharmacologically active ingredient, which is toxic or induces nausea or addiction at oral, but not at transdermal administration is disclosed. The method comprises adding to said transdermal therapeutic system a substance being able to keep off a human being from said ingestion.

Abstract: A process for inscription of a sheet-like adhesive system of a polymer, preferably on the adhesive-free side thereof, with information is characterized in that the inscription is carried out with the aid of a movably guided laser beam in such a manner that a detrimental influence on the ingredients contained in the system, in particular by heat generated by the laser beam or by detrimental perforation of a backing layer impermeable to ingredients or water vapour, is avoided, and that to this end the intensity and penetration depth of the laser beam is adjusted according to the material properties of the system in such a way that the laser beam does not penetrate far enough to reach an ingredient-containing layer of the system.

Abstract: A form of administration for oral administration of active substances, comprising a carrier matrix and at least one active substance, is characterized in that it has a carrier matrix containing a plurality of particles having open pores or capillary spaces which serve as active substance reservoir and contain at least one active substance.

Abstract: Administration forms for application to the skin or mucosa, comprising a carrier matrix and at least one active substance, are characterized in that the carrier matrix has a plurality of particles having open pores or containing capillary spaces, said particles serving as active substance reservoir and containing at least one active substance.

Abstract: The invention relates to the use of deoxypeganine, as free base or as acid addition salt, for the treatment of cerebral, central nervous or psychiatric symptoms, defunctionalization manifestations or disorders occurring through intake of psychotropic substances as a consequence of occasional or chronic abuse of addictive substances, intoxicants or medicines, or as side effects of the use, especially repeated or prolonged, as intended of medicaments, or as an effect of use, in particular repeated or prolonged, not as intended of medicaments, or as a result of acute poisoning by psychotropic toxic substances, or as a result of chronic exposure to toxic substances with a psychotropic effect in humans or other vertebrates.

Abstract: The invention relates to the use of galanthamine, as free base or as acid addition salt, for the treatment of cerebral, central nervous or psychiatric symptoms, defunctionalization manifestations or disorders occurring through intake of psychotropic substances as a consequence of occasional or chronic abuse of addictive substances, intoxicants or medicines, or as side effects of the use, especially repeated or prolonged, as intended of medicaments, or as an effect of use, in particular repeated or prolonged, not as intended of medicaments, or as a result of acute poisoning by psychotropic toxic substances, or as a result of chronic exposure to toxic substances with a psychotropic effect in humans or other vertebrates.

Abstract: A method for the protection of a human being against any health impairment as a result of the ingestion of the whole or parts of a transdermal therapeutic system containing at least one pharmacologically active ingredient, which is toxic or induces nausea or addiction at oral, but not at transdermal administration is disclosed. The method comprises adding to said transdermal therapeutic system a substance being able to keep off a human being from said ingestion.

Abstract: Methods for the treatment of patients are provided, such methods comprising applying to the patient a transdermal therapeutic system comprising a therapeutically effective substance such that the dosage of the therapeutically active substance remains constant over a prolonged period of time.

Abstract: The invention concerns a transdermal application system for antithrombotic therapy and for the prophylaxis against cancer, respectively, containing as active substance acetylsalicylic acid and/or pharmaceutically acceptable salts thereof.

Abstract: A volume-expandable, sheet-like application form suitable as an active substance carrier, in particular for oral application, in the form of a film comprising a mixture of fillers, cleansers, cosmetics, or active substances, film formers, and softeners has portions of a highly absorbent hydrogel former which swells on contact with water and assumes several times its original volume.

Abstract: A method for the application of an active substance patch for controlling or alleviating an addiction such as drug addiction, addiction to pills or analgesia is characterized in that two or more active substance patches are applied simultaneously, sequentially or alternately within a given therapy plan under surveillance of the blood level of the active substance in a way that allows the achievement of an active substance blood level which is high enough for a successful suppression of the addiction and remains constantly effective throughout a useful period of administration.

Abstract: A childproof package for active substance patches is formed as primary package and comprises at least one mechanically tough, in particular tear-resistant layer.

Abstract: In a process for the production of a transdermal therapeutic system for the administration of active substances to the skin in the form of a plane multichamber or multichamber-channel system an active substance-containing layer is introduced between top layer and bottom layer; subsequently top and bottom layer are squeezed at individual and/or coherent sites under displacement of the intermediary sites of the active substance-containing layer and formation of active substance-containing chambers or channels, and at the same time or after that top layer and bottom layer are bonded permanently at the squeezed places.

Abstract: The invention relates to a fixing system for fixing catheters, cannulas, etc. with a skin film (3) coated with a skin adhesion layer (2) and having a cover film (1) and an overplaster (6) finished with a pressure sensitive adhesive layer (5) adhering to the skin film and having an overplaster cover layer (4), as well as to a process for the sterile fastening of a cannula to the skin with the following steps: application of a bacteria-tight skin film with skin adhesion layer to the skin in the insertion region of the cannula, passing the cannula through the skin film, applying an adhesive forming an elastic, bacteria-tight film adhering to the skin film region surrounding the insertion point and the cannula portion projecting out of the skin and sticking the overplaster over the cannula.

Abstract: The invention relates to a transdermal therapeutic system for administering or applying active substances to the skin with a backing layer remote from the skin, an active substance depot, an active substance delivery control means controlling the delivery of the active substance through the system and a contact adhesive means for fixing the therapeutic system to the skin, in which the active substance depot is a multichamber system, in which discreet chambers contain one or more active substances.

Abstract: The invention relates to a transdermal therapeutic system for administering or applying active substances to the skin with a backing layer remote from the skin, an active substance depot, an active substance delivery control means controlling the delivery of the active substance through the system and a .[.contact.]. .Iadd.pressure sensitive .Iaddend.adhesive means for fixing the therapeutic system to the skin, in which the active substance depot is a multichamber system, in which discreet chambers contain one or more active substances.